People

Philippe Guillaume is explicitly named by Porsolt as a safety-pharmacology study director in its current2026 white-paper announcement. Published work covers cardiovascular telemetry, hERG assays, exposure–QTc analysis and integrated CNS, respiratory and cardiovascular safety profiling for investigational drug-development programmes.